Experience of using an interferon inducer in the prevention of influenza and acute respiratory viral infections in children

Author:

Borisova O. V.1ORCID,Bochkareva N. M.1ORCID,Polezhaeva N. S.1,Yashkina O. N.1,Tsareva N. G.1,Gadelshina D. M.1

Affiliation:

1. Samara State Medical University

Abstract

Introduction. Taking into account the changeable viral landscape of pathogens, the persistence of seasonal morbidity at a high level, and the refusal of a number of parents to be vaccinated against influenza, the interest of scientists and practitioners in the use of endogenous interferon inducers is increasing. Studies by domestic authors have proven that Kagocel® is highly effective in the prevention and treatment of influenza and other ARIs.Aim. Evaluation of the efficacy and safety of Kagocel® for the prevention of influenza and ARIs in children aged 3–18 years old on an outpatient basis during the epidemic rise of respiratory viral infections in 2022–2023.Materials and methods. A prospective comparative analysis of cases of prevention of influenza and ARIs by Kagocel® in children was carried out: group 1 – main (n = 32). Kagocel® was prescribed according to the scheme for a month. The comparison group consisted of patients vaccinated against influenza, who did not receive drugs for the prevention of acute respiratory viral infections: group 2 – comparison (n = 28).Results and discussion. The index of preventive efficacy of Kagocel® was 3.0, the efficiency ratio was quite high – 66.7%. The elimination of the main clinical symptoms of the disease was noted on average by the 2nd–3rd day of illness. Prophylactic  administration of the drug allowed to reduce the incidence of influenza and ARIs by 3 times; reduce the number of complications from these diseases by 4 times. The economic feasibility of prophylaxis with Kagocel® has been proven, direct costs for the treatment of one patient have decreased by 3.6 times. The interferon inducer was well tolerated, no side effects of the drug were detected.Conclusion. Endogenous interferon inducer Kagocel® can be used for prophylactic purposes during the seasonal rise in the incidence of influenza and ARIs.

Publisher

Remedium, Ltd.

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3